Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenx	$629.51 +1.4%	$597.89	$352.77 ▼ $678.21	$38.44B	0.6	307,559 shs	231,101 shs
BNTX BioNTech	$104.00	$101.41	$76.53 ▼ $131.49	$24.96B	1.07	906,125 shs	1.22 million shs
GMAB Genmab A/S	$20.79 +0.8%	$20.45	$17.24 ▼ $30.41	$13.76B	1.07	1.05 million shs	1.23 million shs
TAK Takeda Pharmaceutical	$15.28 +0.8%	$14.75	$12.58 ▼ $15.37	$48.62B	0.39	1.86 million shs	1.11 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenx	+1.01%	+4.24%	+5.40%	-4.19%	+66.57%
BNTX BioNTech	+1.94%	+2.15%	+9.53%	-16.33%	+19.25%
GMAB Genmab A/S	+0.19%	+2.79%	+3.67%	+5.36%	-26.71%
TAK Takeda Pharmaceutical	+0.93%	+1.54%	+0.76%	+13.34%	+16.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenx	3.1657 of 5 stars	3.5	2.0	0.0	3.5	1.7	1.9
BNTX BioNTech	2.3874 of 5 stars	4.4	2.0	0.0	2.2	0.8	0.0
GMAB Genmab A/S	4.441 of 5 stars	4.3	5.0	0.0	3.5	0.0	3.1
TAK Takeda Pharmaceutical	2.5843 of 5 stars	0.0	4.0	1.7	2.7	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenx	2.91	Moderate Buy	$699.28	11.08% Upside
BNTX BioNTech	2.89	Moderate Buy	$143.44	37.92% Upside
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	88.39% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest GMAB, TAK, ARGX, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2025	ARGX argenx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$681.00 ➝ $796.00
4/11/2025	ARGX argenx	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00 ➝ $715.00
4/9/2025	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $37.00
4/8/2025	ARGX argenx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00 ➝ $720.00
4/2/2025	TAK Takeda Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight
4/1/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$150.00 ➝ $145.00
4/1/2025	GMAB Genmab A/S	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform
3/17/2025	ARGX argenx	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/12/2025	ARGX argenx	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Hold
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenx	$2.19B	17.55	N/A	N/A	$69.22 per share	9.09
BNTX BioNTech	$2.75B	9.07	$4.47 per share	23.25	$92.17 per share	1.13
GMAB Genmab A/S	$21.53B	0.64	$1.40 per share	14.80	$8.04 per share	2.59
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.58 per share	4.27	$15.39 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenx	-$295.05M	$12.59	N/A	58.02	N/A	-2.11%	-1.45%	-1.29%	5/8/2025 (Estimated)
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
GMAB Genmab A/S	$1.14B	$1.74	11.95	11.68	2.65	36.30%	16.78%	13.79%	5/8/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.40	38.20	9.26	0.24	4.53%	9.39%	4.53%	5/8/2025 (Estimated)

Latest GMAB, TAK, ARGX, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ARGX argenx	$0.98	N/A	N/A	N/A	$748.34 million	N/A
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.26	N/A	N/A	N/A	$5.17 billion	N/A
5/5/2025	Q1 2025	BNTX BioNTech	-$2.68	N/A	N/A	N/A	$175.90 million	N/A
3/10/2025	Q4 2024	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/27/2025	Q4 2024	ARGX argenx	$0.98	$1.58	+$0.60	$11.79	$678.52 million	$761.22 million
2/12/2025	Q4 2024	GMAB Genmab A/S	$0.28	$0.57	+$0.29	$0.85	$884.02 million	N/A
1/30/2025	Q3 2025	TAK Takeda Pharmaceutical	$0.34	$0.42	+$0.08	$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenx	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	$1.53	1.47%	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.53	3.47%	-8.36%	132.50%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenx	N/A	8.53	7.88
BNTX BioNTech	0.01	7.33	7.21
GMAB Genmab A/S	N/A	5.25	5.24
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenx	60.32%
BNTX BioNTech	15.52%
GMAB Genmab A/S	7.07%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ARGX argenx	2.43%
BNTX BioNTech	19.20%
GMAB Genmab A/S	1.54%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenx	650	61.06 million	59.29 million	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
GMAB Genmab A/S	1,660	661.97 million	651.58 million	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

GMAB, TAK, ARGX, and BNTX Headlines

Recent News About These Companies

JPMorgan Chase & Co. Has $1.11 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 29 at 3:06 AM | marketbeat.com

‘Made in India’ dengue vaccine likely to be launched next year. Here’s what we know

April 28 at 1:04 PM | firstpost.com

Syon Capital LLC Has $486,000 Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 27 at 5:58 AM | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Acquired by Mariner LLC

April 27 at 4:03 AM | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Purchased by First Trust Advisors LP

April 26 at 4:56 AM | marketbeat.com

XTX Topco Ltd Trims Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 26 at 4:15 AM | marketbeat.com

Teduglutide improves stool outcomes in children with short bowel syndrome over 96 weeks

April 25, 2025 | healio.com

Japanese pharmaceutical firm Takeda’s profits hit by €37m impairment charge

April 24, 2025 | msn.com

Why Recursion Pharmaceuticals, Inc.’s (RXRX) Stock Is Up 7.02%

April 23, 2025 | aaii.com

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025

April 23, 2025 | kansascity.com

5 minutes with… Dr Tami Nussbaum, Takeda

April 23, 2025 | emjreviews.com

Capital Research Global Investors Buys 25,309 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 23, 2025 | marketbeat.com

Sterling Capital Management LLC Cuts Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 23, 2025 | marketbeat.com

How Takeda's CEO transformed the company into a global pharma powerhouse

April 23, 2025 | msn.com

Japan drug companies offer rare haven amid Trump market jitters

April 22, 2025 | asia.nikkei.com

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

April 21, 2025 | zacks.com

Forum Financial Management LP Acquires 65,399 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 21, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Position Trimmed by Cerity Partners LLC

April 21, 2025 | marketbeat.com

Envestnet Asset Management Inc. Sells 460,843 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

April 19, 2025 | marketbeat.com

Towards gene-targeting drugs capable of targeting brain diseases

April 17, 2025 | sciencedaily.com

Cholesterol-modified oligonucleotides show promise for treating brain diseases

April 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

5 Hot Stock Buys for Investors in April
By Thomas Hughes | April 1, 2025
View 5 Hot Stock Buys for Investors in April
NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
By Sam Quirke | April 3, 2025
View NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?
Buffett’s Next Oil Bet: Why Occidental Is Different
By Jea Yu | April 8, 2025
View Buffett’s Next Oil Bet: Why Occidental Is Different
United States Steel's Crash: An Unmissable Buying Opportunity
By Gabriel Osorio-Mazilli | April 11, 2025
View United States Steel's Crash: An Unmissable Buying Opportunity
IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
By Leo Miller | April 12, 2025
View IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead

GMAB, TAK, ARGX, and BNTX Company Descriptions

argenx NASDAQ:ARGX

$629.51 +8.54 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$629.45 -0.06 (-0.01%)

As of 06:15 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

BioNTech NASDAQ:BNTX

$104.00 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$102.05 -1.95 (-1.88%)

As of 06:59 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Genmab A/S NASDAQ:GMAB

$20.79 +0.16 (+0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$20.79 0.00 (0.00%)

As of 04:05 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Takeda Pharmaceutical NYSE:TAK

$15.28 +0.12 (+0.79%)

Closing price 03:59 PM Eastern

Extended Trading

$15.21 -0.07 (-0.46%)

As of 05:08 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time